TET2 and myelodysplastic syndrome: Collectively, these findings indicate that SIRT1 activation can be considered a novel therapeutic approach to regulate the activity of Tet2 in MDS HSPCs and support more detailed explorations of the SIRT1/Tet2 axis as a potential opportunity for exploitation in MDS (Sun et al., 2018).